An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Phase of Trial: Phase III
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms DELIVER
- Sponsors AstraZeneca
- 04 Sep 2018 Planned End Date changed from 25 Jun 2021 to 22 Jun 2021.
- 04 Sep 2018 Planned primary completion date changed from 25 Jun 2021 to 22 Jun 2021.
- 04 Sep 2018 Status changed from not yet recruiting to recruiting.